

Rev03 DATASHEET

Update: Dec,14,2021

SARS-CoV-2 Spike protein (S1, E484Q, L452R, His Tag)


Cat. No.: Z03609

Product Introduction

Species	SARS-CoV-2
Protein Construction	
	S1 protein [Gln14-Arg685 (E484Q, L452R)] Poly-His Accession # P0DTC2
	N-term C-term
Purity	≥ 95% as analyzed by SDS-PAGE
Endotoxin Level	< 0.2 EU/μg of protein by gel clotting method
Biological Activity	This protein is validated to bind with human ACE2 in functional ELISA assay.
Expression System	СНО
Theoretical Molecular Weight	75.7 kDa
Formulation	Supplied as a solution in PBS, pH 7.4.
Concentration	Please refer to the COA for the specific lot.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at -20°C or below. Please avoid repeated freeze-thaw cycles.

Examples





Immobilized ACE-2 Fc Chimera, Human at 2 μg/mL can bind SARS-CoV-2 Spike protein (S1, E484Q, L452R, His Tag) (Cat. No. Z03609) with a serial dilution.

THETM His Tag Antibody [HRP], mAb, Mouse (Cat.No.A00612) is used as a secondary antibody (0.2 μ g/mL).

Background

Target Background: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Lineage B.1.617, also known as G/452.V3, was first identified in October 2020 in India. This variant has the double mutations E484Q and L452R in the spike proteins. Emerging research suggests the variant may be more transmissible than previously evolved ones. Whether the effectiveness of currently-deployed vaccines is affected remains under investigation. Moreover, the sublineages B.1.617.2 has been redesignated as "variant of concern" (VOC-21APR-02) in May 2021, which spreads more quickly than the original version of the virus.

Synonyms: Lineage B.1.617; G/452.V3; "double mutation" variant; India variant; Kappa variant

References:

- 1. COVID-19 Weekly Epidemiological Update.
- 2. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
- 3. SARS-CoV-2 variants of concern and variants under investigation in England.

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.